Ethylmorphine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ethylmorphine (codethyline) — also known as dionine — is a semi-synthetic opioid of the morphinan class. It is the closest pharmaceutical relative of codeine, separated by a single carbon in the ether chain at the 3-position. The liver converts it to morphine, which activates opioid receptors and produces the pain suppression and sedation characteristic of the opioid class.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, codeine, oxycodone +3 moremorphine, codeine, oxycodone, hydrocodone, heroin, all mu-opioid agonists show less
First synthesized by Merck in Germany in 1884, it was developed as a weaker alternative to morphine for pain and cough suppression. It became a prescription cough suppressant in France and Norway from 1953 onward. It remains available by prescription in several European countries and has never been approved in the United States.
Subjective effects include pain relief, warmth, bodily heaviness, mild euphoria, sedation, and anxiolysis. The experience is gentler than morphine — onset is gradual and the ceiling lower, reflecting the metabolic bottleneck of liver conversion. Nausea, constipation, and respiratory depression are characteristic unwanted effects.
Ethylmorphine produces physical dependence with regular use, and the fatal blood concentration is roughly nine times the level found in impaired drivers.[1][2] Genetics determine how much morphine the body makes from a given dose,[3] and combining with alcohol creates a dual-mechanism lethal risk.[4] Most of what is known comes from pharmacokinetic studies and forensic reports, not controlled trials.
History[edit]
Discovery
Ethylmorphine was first synthesized by Merck in Germany in 1884,[5] during the same wave of semi-synthetic opioid development that produced heroin. It was designed to reduce potency while preserving the cough-suppressing and analgesic properties of morphine.[5] Its earliest clinical use was as an eye analgesic — a 1904 paper in the British Medical Journal described its ophthalmic application under the brand name Dionine.[6]
Clinical adoption
Ethylmorphine's modern role began in 1953, when it was launched in France as a cough suppressant under the name Codethyline, followed by Norway and Spain in 1960.[5] In Norway, it became the active ingredient in Cosylan, a prescription cough syrup that remained in clinical use for decades.[7][8] It was never approved for use in the United States.[5]
Scheduling and abuse
International control came under the 1961 Single Convention on Narcotic Drugs, Schedule II.[5] Despite its reputation as a mild opioid, forensic evidence documents patterns of abuse — hair analysis in a fatal overdose revealed a switch from heroin to ethylmorphine,[1] and impaired-driving data confirmed its recreational use.[2]
The name Dionine — ethylmorphine's original brand — derives from its earliest use as an ophthalmic preparation. The alternate name codethyline reflects its structural kinship with codeine, positioning it as the ethyl structural analog in the same chemical series. Neither name carries cultural weight outside pharmaceutical history; ethylmorphine has never developed the street identity or subcultural mythology of morphine or heroin.
Chemistry[edit]
Structural class
Ethylmorphine belongs to the morphinan chemical class.[5] It is the 3-O-ethyl ether of morphine — structurally identical to morphine except that a short ethyl chain replaces the 3-hydroxyl group.[9] This places it in a direct series with codeine, differing by a single carbon.
| Molecular formula | C₁₉H₂₃NO₃ |
| Molecular weight | 313.4 g/mol |
The ethyl group at the 3-position weakens direct opioid receptor binding compared to morphine and codeine.[10] This makes ethylmorphine a prodrug: the liver must regenerate morphine before the compound can produce its opioid effects.[5][7] The hydrochloride salt is the standard pharmaceutical form used in marketed preparations.[8]
Pharmacology[edit]
Mechanism of action
Ethylmorphine functions as a prodrug — its opioid effects are not produced by the parent compound but by morphine, generated when the liver converts it.[5][7] The parent compound binds opioid receptors very weakly on its own.[10] Once formed, morphine activates opioid receptors throughout the brain and spinal cord, producing pain suppression, euphoria, cough suppression, sedation, and respiratory depression.[11][12]
Pharmacokinetics
Ethylmorphine is broken down in the liver along three pathways: conversion to morphine (the pharmacologically important one), N-demethylation to norethylmorphine,[4][13] and glucuronidation — the most abundant urinary metabolite.[7] After a single oral dose, peak blood levels arrive in about 45 minutes with the syrup and about 2 hours with tablets.[7][14]
The amount of morphine produced varies dramatically between people. A liver enzyme called CYP2D6 controls this conversion — poor metabolizers produce about 3% morphine from a given dose, while extensive metabolizers produce about 11%.[3] Ethylmorphine also produces proportionally more morphine per milligram than an equivalent dose of codeine.[3]
Neuroscience[edit]
Where it acts
Ethylmorphine's brain effects are those of morphine, acting on key neural circuits. In the mesolimbic pathway, opioid receptor activation triggers dopamine release — producing euphoria and reinforcing repeated use.[11] In the pain pathways running from brain to spinal cord, the same activation suppresses incoming pain signals.[11]
In brainstem breathing centers, morphine slows respiration in a dose-dependent way.[11] This is the mechanism behind opioid overdose death — the dose that stops pain can, in excess, stop breathing.
Why it matters
Regular opioid use suppresses the brain's own natural opioid system. The brain reduces its internal opioid peptide production over time. When the drug stops, the system cannot immediately recover — producing the withdrawal of muscle pain, restlessness, anxiety, runny nose, and autonomic instability.[11]
CYP2D6 ultrarapid metabolizer risk: Individuals carrying gene duplications for the enzyme that converts ethylmorphine to morphine may produce dangerously high morphine levels from standard doses. Fatal outcomes have been documented for codeine in this population, but equivalent investigation for ethylmorphine has not been conducted.citation needed
Subjective Effects[edit]
The experience of ethylmorphine is shaped by its prodrug nature. Effects build gradually as the liver converts the compound to morphine — slower and softer than direct-acting opioids. The result is a warm, heavy, quietly content state: anxiety dissolves, pain recedes, and the body settles into a weighted calm.
Relative to codeine, ethylmorphine delivers a modestly stronger opioid character per milligram — sitting between codeine and low-dose morphine in intensity. Its most distinctive feature is pharmacogenomic unpredictability: the same dose produces minimal effect in some people and a strong opioid response in others, depending on how efficiently the liver converts the compound.
Effect Grid
Clear mu-opioid agonist effects emerge — moderate analgesia, noticeable sedation, and a warm euphoric contentment. Anxiety suppression is pronounced. Pupil constriction is visible and consistent. The antitussive ceiling is reached within this range.
Bodily heaviness and muscle relaxation are prominent. Nausea is possible, particularly in opioid-naive users. Constipation onset begins. Mild respiratory slowing occurs but is typically not subjectively distressing at this level. A body high characterized by diffuse warmth and spontaneous pleasant sensations is common.
Cognitive effects include thought deceleration, focus suppression, and mild motor control impairment. This range straddles the upper therapeutic boundary — doses above 50 mg exceed published therapeutic recommendations.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Body high · Constipation · Pain suppression · Bodily heaviness · Breathing alteration · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Appetite suppression · Dry mouth · Sexual arousal suppression · Vomiting · Yawning · Excessive sweating · Temperature dysregulation · Heart rate perception changes · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Bodily heaviness · Breathing alteration · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Appetite suppression · Dry mouth · Sexual arousal suppression · Vomiting · Yawning · Excessive sweating · Heart rate perception changes · Involuntary body movements · Nystagmus (eye wobbles) · Bodily dissociation
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria · Amnesia
Information processing suppression · Creativity suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Thought disorganization · Cognitive dysphoria
Disinhibition · Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial absorption begins; effects emerge as CYP2D6 converts ethylmorphine to morphine. Faint warmth and mild anxiolysis are the first signals. Onset timing varies with formulation — syrup reaches Tmax in ~45 min, tablets in ~2.
Progressive deepening of analgesia, sedation, and euphoria as morphine levels build in the CNS. Bodily heaviness and muscle relaxation become noticeable. Pupil constriction begins.
Maximum opioid effects — analgesia, euphoria, sedation, and pupil constriction are fully established. Respiratory depression is dose-dependent and most significant here. Nausea, if it occurs, typically peaks during this phase.
Gradual decline as ethylmorphine (t½ = 2h) and morphine are cleared. Sedation typically outlasts euphoria. Analgesia fades progressively.
Residual sedation and mild warmth linger. Constipation may persist for hours. Opiate immunoassay screens remain positive for 24+ hours post-dose.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- morphine · codeine · oxycodone
Toxicity
Acute toxicity
No established lethal dose exists for ethylmorphine.safety citation needed The one published fatal overdose recorded a blood concentration of 488 ng/mL — roughly nine times the mean level found in impaired drivers.[1][2]
Respiratory depression is how opioid overdose kills: morphine acts on brainstem breathing centers and progressively slows them.[11] This risk rises sharply with dose and with concurrent use of any other depressant.[11]
Liver toxicity
Ethylmorphine depletes the liver's glutathione — a protective molecule — through opioid receptor activation in animal models.[17] Glutathione depletion increases vulnerability to liver damage from paracetamol (acetaminophen).[17]
Psychological risks
Opioids impair attention, reaction time, and decision-making in a dose-dependent way — confirmed by impaired-driving data at therapeutic concentrations.[2]
The cycle of withdrawal-related low mood can worsen pre-existing depression during cessation. Chronic opioid use can also paradoxically increase pain sensitivity — documented for morphine but not specifically studied for ethylmorphine.inferred
Tolerance and dependence
Tolerance develops with repeated use as opioid receptors become less responsive.[11] Cross-tolerance is established with all μ-opioid agonists — morphine, codeine, oxycodone, and related compounds.[12]
Ethylmorphine carries significant abuse liability. Forensic evidence documents heroin users switching to it,[1] impaired-driving cases involving it,[2] and controlled-substance classification across major jurisdictions.[5] Physical withdrawal — muscle aches, insomnia, anxiety, runny nose, sweating, and digestive disturbance — is expected by class inference.inferred
Drug interactions
Combining ethylmorphine with other depressants — especially alcohol, GHB/GBL, benzodiazepines, or other opioids — risks fatal respiratory depression. The ethylmorphine–alcohol interaction operates through dual mechanisms, making the lethal risk particularly difficult to predict.Alcohol is the most critical interaction. Ethanol inhibits all three metabolic pathways: morphine formation reduced 44%, N-demethylation reduced 35%, and glucuronidation reduced 30–60%.[4] Total elimination slows by 38%.[4] Higher parent drug levels combine with additive respiratory depression — two mechanisms together toward a lethal outcome.
GHB and GBL add to respiratory and central nervous system depression from opioids. GHB alone can cause death via cardiorespiratory collapse;[18] GBL converts to GHB within about one minute of ingestion.[18]
Tramadol adds opioid respiratory depression, lowers the seizure threshold,[19][20] and carries serotonin syndrome risk in polypharmacy contexts.[19]
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) reduce conversion of ethylmorphine to morphine, potentially decreasing analgesic effect while altering the metabolic profile unpredictably.[6]
CYP3A4 inducers (barbiturates, rifampin, carbamazepine) accelerate an alternate metabolic pathway, potentially reducing ethylmorphine's effectiveness.[6]
Paracetamol (acetaminophen): Ethylmorphine depletes liver glutathione,[17] increasing vulnerability to paracetamol-induced liver damage.
Contraindications
Breathing difficulties (absolute): Asthma, COPD, and other conditions compromising lung function are absolute contraindications — opioids depress breathing.[5][6]
Concurrent depressant use (absolute): Combination with alcohol, benzodiazepines, barbiturates, GHB/GBL, or other opioids is contraindicated due to additive respiratory depression.[4]
Children (absolute): Ethylmorphine is contraindicated in children under approximately 8 years of age.[6] Pediatric ultrarapid metabolizers face amplified risk of morphine toxicity.
Intravenous use (absolute): IV administration risks dangerous histamine release.[6]
Ultrarapid metabolizer status (relative): Individuals who convert the drug to morphine unusually quickly face elevated toxicity risk from standard doses — established by analogy with codeine.[12]inferred
Liver impairment (relative): Pre-existing liver disease may alter both effectiveness and toxicity, given the drug's dependence on liver metabolism and its glutathione-depleting effects.[17]
Driving and machinery operation: Psychomotor impairment is documented at therapeutic and above-therapeutic concentrations.[2]
Harm Reduction[edit]
Forms & Identification
Ethylmorphine circulates almost exclusively as manufactured pharmaceutical products — primarily cough syrups and tablets — rather than as unregulated substances. Identification is mainly a matter of verifying that a commercial product is genuine and unexpired.
The main identification risk is confusion with other opioid preparations. Pharmaceutical ethylmorphine products are region-specific (Cosylan in Norway, Codethyline formulations in France) and may be unfamiliar outside their home markets. Verify the product name, manufacturer, and active ingredient against known formulations before use.
Guidelines
- Use only pharmaceutical-grade preparations from verified sources.
- Start with the lowest available dose, particularly if CYP2D6 metabolizer status is unknown — individual conversion to morphine varies ninefold.
- Do not combine with alcohol, benzodiazepines, GHB/GBL, or other opioids under any circumstances.
- Do not combine with paracetamol (acetaminophen) due to shared liver toxicity.
- Allow adequate time between doses — the 2-hour half-life means effects from repeated dosing accumulate.
- Do not use alone, particularly at higher doses or during initial use when individual sensitivity is unknown.
- Avoid driving or operating machinery.
Set & Setting
Opioid effects are shaped less by psychological set and environmental setting than psychedelics or empathogens. Using ethylmorphine in a safe, comfortable environment reduces risk — sedation and psychomotor impairment increase the danger of falls, accidents, and decision impairment. Avoid situations requiring alertness, coordination, or driving.
Aftercare & integration. Following opioid use, allow the body adequate recovery time. Mild rebound effect discomfort, irritability, or low mood may occur as effects wear off — these typically resolve within 24–48 hours after occasional use.
Stay hydrated and eat light meals — opioids suppress appetite and slow digestion. Constipation may persist for a day or more. If use was motivated by emotional distress or pain avoidance, seek professional support before repeating.
Recovery & Support
Ethylmorphine, like all μ-opioid agonists, produces physical dependence with regular use. Withdrawal symptoms — muscle aches, insomnia, anxiety, runny nose, sweating, and digestive disturbance — typically begin within hours of the last dose and peak at 48–72 hours.
Medical supervision during withdrawal is recommended — healthcare providers can manage symptoms with appropriate medications. Abrupt cessation after prolonged use is uncomfortable but rarely life-threatening, unlike withdrawal from alcohol or benzodiazepines.
Opioid-specific treatment includes medication-assisted treatment with buprenorphine or methadone, which stabilize opioid receptor activity and reduce cravings. Peer support communities, counseling, and addiction medicine specialists are accessible through national helplines and local treatment directories.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing has slowed, become shallow, or stopped
- Lips, fingertips, or skin turning blue or grey
- Person is unresponsive to voice or physical stimulation
- Gurgling, choking, or snoring sounds in an unconscious person
Immediate steps:
- 1. Call emergency services immediately.
- 2. If naloxone is available, administer it — naloxone reverses opioid respiratory depression. A second dose may be needed after 2–3 minutes if breathing does not improve.
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. Stay with the person until help arrives — naloxone wears off faster than most opioids, and respiratory depression may return.
- 5. Do NOT induce vomiting in an unconscious person.
What to tell the dispatcher: Describe the substance taken (ethylmorphine / opioid cough medicine), the amount if known, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Naloxone (Narcan) reverses opioid respiratory depression and is the specific antidote. It is available without prescription in many jurisdictions.
Legal Status[edit]
Ethylmorphine is controlled internationally under the 1961 United Nations Single Convention on Narcotic Drugs, placed in Schedule II, with dilute preparations (≤100 mg per dosage unit, ≤2.5% concentration) listed in Schedule III.[5] It remains available by prescription as a cough suppressant in several countries and has never been approved in the United States.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (pure); Schedule III/V (combinations) | Pure ethylmorphine is Schedule II. Combinations with non-narcotic ingredients at ≤100 mg/100 mL or ≤15 mg/dosage unit are Schedule III. No US-marketed products exist[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled as a Class B substance[5] |
| Canada | Schedule I (CDSA) | Highest domestic scheduling level[5] |
| Australia | Schedule 8 (Drugs of Dependence) | Lower-concentration combination products may fall under Schedule 2 or 4 |
| Germany | Prescription-only; higher doses Anlage II (BtMG) | Standard doses require prescription; higher-dose formulations controlled under the Betäubungsmittelgesetz[5] |
| Brazil | Class A2 narcotic | Classified as a narcotic substance[5] |
| France | Prescription (Codethyline) | First market for modern antitussive formulation (1953); available by prescription[5] |
| Norway | Prescription (Class B / Rx) | Marketed as Cosylan (1.7 mg/mL ethylmorphine HCl) for antitussive use[7] |
Forensic considerations
Ethylmorphine is metabolized to morphine. Following ingestion, urine tests positive for morphine on standard opiate immunoassays — 100% of subjects tested positive within 24 hours of a single oral dose of 25–50 mg.[21] The morphine-to-ethylmorphine ratio exceeds 1.0 by 12–24 hours,[21] meaning a positive morphine test may originate from ethylmorphine, codeine, heroin, or direct morphine use. Norethylmorphine is the recommended additional marker to identify ethylmorphine as the source.[7]
references
- [1] ^abcdKintz P, Jamey C, Mangin P (1994) Ethylmorphine concentrations in human samples in an overdose case — Archives of Toxicology PMID:8024470
- [2]
- [3] ^abcHedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R (1997) Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity — Therapeutic Drug Monitoring PMID:9421105
- [4]
- [5]
- [6]